| Clinical Trials
Clinical Trials

Effect of a Change in Lasmiditan Dose on Drug Efficacy and Safety: Phase 3 Study Findings

book_2 Source: AHSAM 2020 - Poster session Published on July 23, 2020 
calendar_today Published on Medfyle: July 2020
headphones 3 min

In this medfyle

Podcast by Jessica Ailani, MD

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • The study assessed the effects of a lasmiditan dose change on efficacy and safety among patients who treated their first migraine attack using placebo, 50 mg, 100 mg, or 200 mg in blinded, Phase 3 single attack SAMURAI or SPARTAN and then took 100 mg or 200 mg for their first migraine attack in open-label GLADIATOR.
  • There was a small dose response for lasmiditan, with higher doses providing an improved chance at pain freedom.
  • The efficacy of lasmiditan versus most common treatment-emergent adverse event benefit-risk ratio appears to improve with higher doses, particularly as incidence of TEAEs decrease with subsequent migraine attack dosing.
Presenting Author
Read more arrow_downward Hide arrow_upward

Jessica Ailani, MD
Director Medstar Georgetown Headache Center, Associate Professor Neurology
Department of Neurology, Georgetown University Hospital
Washington D.C., District of Columbia

Jessica Ailani is a Professor of Clinical Neurology, Director of the Georgetown Headache Center, and Vice Co-Chair of Strategic planning Neurology at MedStar Georgetown University Hospital in Washington, DC. Dr. Ailani is a fellow of the American headache society and the American Academy of Neurology. She holds a position on the board as a member at large, is the co-chair of the Practice management group and is on the scientific and Scottsdale program planning committees . She is section editor of Unusual Headache Syndromes for Current Pain and Headache Reports and a reviewer for several professional journals. Dr. Ailani has presented nationally on topics surrounding headache medicine. 


Author disclosures
Read more arrow_downward Hide arrow_upward

Jessica Ailani, MD: Alder Biopharmaceuticals (Consulting Fees (e.g., advisory boards)) Allergan (Consulting Fees (e.g., advisory boards)) Amgen (Consulting Fees (e.g., advisory boards)) Biohaven (Consulting Fees (e.g., advisory boards)) ElectroCore LLC (Consulting Fees (e.g., advisory boards)) Eli Lilly and Company (Consulting Fees (e.g., advisory boards)) Impel Neuropharma (Consulting Fees (e.g., advisory boards)) Promius (Consulting Fees (e.g., advisory boards))Revance (Consulting Fees (e.g., advisory boards)) Satsuma (Consulting Fees (e.g., advisory boards)) Teva Pharmaceuticals (Consulting Fees (e.g., advisory boards)) Zosano (Consulting Fees (e.g., advisory boards))